Thursday, September 22, 2022
HomeNewsWhat Is The Future Of Alzheimer's Disease

What Is The Future Of Alzheimer’s Disease

Highlights From The Canadian Chronic Disease Surveillance System

What causes Alzheimer’s Disease?

According to the World Health Organization, 47.5;million people live with dementia, including Alzheimer’s disease, worldwide.Footnote 1 As these conditions progress, they become highly debilitating for affected individuals and lead to major health impacts. With a growing and aging population, the number of Canadians living with dementiaFootnote i is expected to increase in future decades, with corresponding implications for health care needs and use. By 2031, it is projected that the total annual health care costs for Canadians with dementia will have doubled those from two decades earlier, from $8.3;billion to $16.6;billion.Footnote 2

Using data from the Canadian Chronic Disease Surveillance System , the Public Health Agency of Canada is able to conduct national surveillance for diagnosed dementia, including Alzheimer’s disease, to support the planning and evaluation of related policies, programs, and services. This fact sheet presents an overview of these new estimates on diagnosed dementia and highlights information on associated health impacts collected through the National Population Health Study of Neurological Conditions.Footnote 3

The Future Of Alzheimers Disease Detection Could Be As Simple As A Blood Test

Alzheimers disease is best known for its cognitive symptoms, like memory loss and confusion. These symptoms can appear without warning, and from that point, gradual mental decline is unpredictable and nearly inevitable. But inside the brain of a patient, proteins accumulate into formations called amyloid plaques that interfere with signaling between brain cells. Amyloid build-up is not a sure sign of AD, but it is associated with a higher risk of the condition. Unfortunately, it is nearly impossible to get a close look at the brain until the patient is dead. Alternatives are brain scans or measuring protein levels in the fluid that surrounds the brain, but these are both difficult procedures, and especially impractical for regular monitoring of asymptomatic patients.

Although this doesnt point to strategies for better treatment or prevention, it suggests that windows into brain health might be more accessible than previously thought. With further studies that link blood test results to definitive AD diagnoses, AD might become as easy to detect as diabetes or high cholesterol, and improve the possibility of finding and providing a treatment long before symptoms occur.

Managing Correspondent:;Aparna Nathan

Success Will Bring New Challenges

Once a drug is proven effective at delaying the onset of MCI, a condition that can be an early stage of AD), or in delaying or stopping progression to AD, there will be interest in combining them to achieve larger therapeutic effects, Gauthier said.; Already combination therapies are widely used to fight cancer and to prevent AIDS in HIV-positive individuals. We should learn from other fields, such as oncology and infectious disease, about optimal trial designs to demonstrate additive benefits, Gauthier said.

He also urged the field to think through how you will use any of these drugs if and when its approved. For example, with a drug like aducanumab, which is delivered to the brain by injection, would the plan be to set up injection clinics?, Gauthier wondered aloud.; And since its a bioengineered drug that will be costly to manufacture, would it mainly be targeted it to ApoE4 carriers and others at greatest risk?; Gauthier also called for clearly defined start and stop rules, including time periods for gauging a drugs effect, as a way to prepare for optimal use of new drugs.

Finally, even as new therapies advance and bring hope, Gauthier feels its important to place a major emphasis on Alzheimers prevention. Non-pharmacologic interventions such as diet and exercise, have shown encouraging results, he said, and need to be part and parcel of the effort to meet Alzheimers challenges.

Read Also: What Is The Difference Between Dementia And Senility

Alzheimers Disease Around The World

Worldwide there are 35 million people with this disease, a number that will double every 20 years; That is, it is expected that by 2030 there will be 65.7 million cases and just over 115 million by 2050According to the international organization Alzheimers Disease International.

The number of cases may be higher in the near future due to the COVID-19 epidemic, because adults over 65 years of age who have experienced severe forms are more likely to develop dementia of the Alzheimers type, as the SARS-CoV-2 virus can affect It causes inflammation of the nervous system, which is associated with neurodegeneration.

Cárdenas Aguayo explains that 70% of cases of dementia are Alzheimers type, which is characterized by cognitive decline that reduces a patients quality of life, making them dependent on the caregiver.

The specialist determines that in more than 99% of cases are sporadicIt does not have a genetic component and usually appears after 65 years of age with only one gradual involvement The percentage is considered familial or hereditaryIt occurs between the ages of 35 and 40, and is usually more aggressive.

Indicators of cognitive symptoms include changes in memory and language. The first is characterized by the presence of frequent forgetfulness, the loss or placing of objects in inappropriate places, the repetition of questions and stories.

;Bacon advocate. Certified creator. Twitteraholic. Tv junkie. Beer fanatic. Internet nerd. Passionate thinker. Reader.

Whats Next Treatments To Slow Or Stop Alzheimers Damage To The Brain

(PDF) Current and Future Treatments in Alzheimer Disease ...

A quarter-century ago, Gauthier was a lead investigator in the trials to bring tacrine to market, the first cholinesterase inhibitor approved by the FDA in 1993 for the treatment of Alzheimers symptoms. ;CI drugs prevent the breakdown of acetylcholine, a chemical produced in the body that serves as a neurotransmitter, meaning it spurs communication between brain cells, which is how memories are made, stored, and retrieved.

Tracrine was pulled off the market for safety reasons in 2013. However, newer CIs, including donepezil;, galantamine and rivastigmine , are widely used in the United States to improve memory and mental functioning in Alzheimers-related dementia.

Whats still needed, and what pharmaceutical development for Alzheimers has lately focused on, are drugs that slow Alzheimers progression. That includes drugs that target the biggest three causative factors of late-onset Alzheimers disease amyloid beta, tau, and inflammation.

The combination of all three of these leads to a gradual loss of synapses and neurons until symptoms become apparent, Gautheir said. Currently, he said, the big effort is to design randomized controlled trials for drugs that target amyloid, tau, & inflammation at the right stage of disease for the right patient.

Another promising anti-amyloid treatment is Biogens aducanumab, an immunotherapy that targets amyloid aggregates .; Early clinical trial results have shown it can reduce amyloid deposits in several regions of the brain.

You May Like: Senile Vs Dementia

How Toxic Proteins Affect Neuron Structure And Survival

Amyloid beta and tau are two toxic molecular substances that accumulate in the brains of patients with Alzheimers disease, creating plaques and tangles and destroying nerve cells. Pew Latin American fellow Guillermo Eastmanwho is conducting research at the University of Virginia under the mentorship of George S. Bloomis investigating how these substances alter the production of different proteins in brain cells and examining how these changes affect neurons survival, structure, and function.

His research aims to uncover the links that connect amyloid beta and tau to neuronal damage as the disease starts to take shape. This work can help provide clues about cellular pathways and structures that begin to deteriorate in Alzheimers cases as well as which processes contribute to plaque growth. Eastman will be looking for advances that can lead to promising new diagnostic tools and treatments.

What Are The Treatment Options For Those With Alzheimers

Treating Alzheimers disease with conventional drugs isnt straightforward, and none actually stop the disease from progressing. Even though they may seem to improve memory function in the short-run, recent evidence suggests the currently U.S. Food and Drug Administration-approved medications may even make the condition worse over time.

The good news is that drugs are not the only treatment option. By taking a functional medicine approach, Dr. Ken Sharlin has developed a highly eective treatment program called the Brain Tune Up! Protocol.

Don’t Miss: Senility Vs Dementia Vs Alzheimer’s

The 2010s: The Era Of Biomarkers

Over the past 20 years great progress was made in identifying in vivo biological markers of AD. Several investigators refined the ability to detect and measure cerebrospinal fluid levels of A and tau protein that were indicative of AD pathology in the brain. Klunk and colleagues developed Pittsburgh compound-B , an agent that binds to A, for use with PET imaging to reveal deposition of amyloid in the brain. Tau-binding agents that can be used with PET imaging have also been recently developed .

Neuroimaging measures of hippocampal, cortical, and general brain atrophy were developed and applied to detect early neurodegenerative changes associated with AD . Other advanced structural and functional neuroimaging methodologies, including resting-state functional MRI and diffusion tensor imaging, have been used to detect pathological changes associated with AD and to create algorithms for classifying AD and MCI . All of these biomarkers have greatly increased the accuracy with which AD pathology in the brain can be detected before the onset of cognitive symptoms, and improved the ability to differentiate AD from other pathologies that lead to dementia.

In addition, a growing number of studies have shown that cognitive measures can be as sensitive as physical biomarkers in predicting progression to dementia . Taken together, these findings strongly suggest that the neurodegeneration of AD may not depend upon prior amyloidosis .

Help With Legal Needs

What Advances in Blood Biomarker Research Could Mean for the Future of Alzheimer’s Disease

Families who cannot afford a lawyer can still prepare documents and express their wishes in advance. Samples of basic health planning documents are available online. Area Agency on Aging officials may provide legal advice or help. Other possible sources of legal assistance and referrals include state legal aid offices, state bar associations, local nonprofit agencies, foundations, and social service agencies.

Visit the National Hospice and Palliative Care Organization for free sample documents.

For help with legal advice, contact the Eldercare Locator.

Recommended Reading: Difference Between Dementia And Senility

Targeted Research New Discoveries

To gain a precise understanding of Alzheimers, scientists needed to understand the role genes play in the disease. Genes orchestrate the production of proteins and other substances that carry out the bodys functions at a molecular level. When research connects a gene flaw or characteristic to a disease, the identified genes are considered potential troublemakers and can become targets of study themselves.

Alzheimer’s Disease Drug Development Pipeline: 2020

Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas , Las Vegas, Nevada, USA

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA

Correspondence

Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, 888 W Bonneville Ave, Las Vegas, NV 89106, USA.

Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas , Las Vegas, Nevada, USA

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA

Correspondence

Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, 888 W Bonneville Ave, Las Vegas, NV 89106, USA.

Recommended Reading: How To Move A Parent With Dementia To Assisted Living

What Is Alzheimers Disease

Alzheimers disease is a brain disorder that causes memory and thinking skills to decline over time. Deterioration occurs slowly, typically over four or more years.In most people the onset of Alzheimers disease appears in their mid-60s aging is the leading risk factor. This is known as late-onset Alzheimers.; Early-onset Alzheimers is less common but can be seen in people as young as 30.

Alzheimers disease is the number one cause of dementia.

Reasons To Be Hopeful About The Future Of Alzheimers Disease

Science, medicine, and the future: Alzheimer

Need encouragement about the future of Alzheimers disease? Are you looking for memory care facilities in Ann Arbor and want to know whats on the horizon for Alzheimers treatment? Struggling with the news of an Alzheimers diagnosis and looking for hope?

There are millions of Americans living with Alzheimers today. Although diagnosis and treatment have improved since the disease has been recognized, the difficulty in finding effective treatments for Alzheimers is a heavy burden for those afflicted and their caregivers and loved ones. But there are many reasons to have hope for the future of Alzheimers disease.;

If youre searching for memory care facilities in Ann Arbor for yourself or a loved one, check out our list of reasons to be positive about the future of Alzheimers.;

  • Growing Awareness. November is national Alzheimers awareness month, giving people affected by the disease a time to talk about it and help others understand the importance of treatment. Celebrities and groups like the Alzheimers Association being more vocal about the disease has also increased awareness.;
  • Dropping Dementia Rates. From 2000-2012, dementia rates fell from 24% to 11.6% in people ages 65 and older.;
  • Blood and Saliva Testing. Reliable blood and saliva tests administered with cognitive testing offer potential for earlier diagnosis. As treatment and prevention improve with research, early detection will be crucial.;
  • Also Check: Does Meredith Have Alzheimer’s

    Alzheimers Disease: A Clinical Perspective And Future Nonhuman Primate Research Opportunities

  • aDepartment of Neurology, Emory University, Atlanta, GA 30312
  • See allHide authors and affiliations

    • For correspondence:
  • Edited by Elizabeth A. Buffalo, University of Washington, Seattle, WA, and accepted by Editorial Board Member Tony Movshon October 30, 2019

    Over 6 Million Americans Suffer From Alzheimer’s

    In recent years, some major drug companies abandoned efforts to research brain diseases, including Pfizer and Boehringer Ingelheim in 2018 in fact, Biogen had given up on Aduhelm at one point during the clinical trials in 2019 before reversing its decision after decades of failure in search of a breakthrough.

    The controversy surrounding the Biogen drug, including its potential cost, comes against a landscape of massive, unmet need for dementia treatment and a disease that costs the U.S. as much as $259 billion annually. More than 6 million Americans have Alzheimer’s or another form of dementia, according to;estimates from the Alzheimer’s Association, and by 2050 that number could reach over 12 million people at a cost of $1 trillion annually.

    That is why some dementia drug experts are focusing on the renewed attention and fresh financing rather than the potential negatives from the Biogen approval, according to Dr. Jeffrey Cummings, a neurologist at the University of Nevada, Las Vegas, who publishes an annual review of the Alzheimer’s drug development pipeline. His research consistently showed the drug-failure rate at 99.6 percent before the Biogen approval, a stark contrast to the 1 out of every 5 cancer drugs that are successful.

    In recent history, The National Institutes of Health spent two to three times more on heart disease and cancer research than on dementia, while a lack of qualified participants for clinical trials also slowed progress.

    You May Like: Does Alzheimer’s Run In Families

    Next In The Dementia Drug Pipeline

    For the handful of other developmental Alzheimer’s drugs hoping to clear those same regulatory hurdles and prove their efficacy Eli Lilly‘s donanemab, Roche’s gantenerumab and Eisei’s lecanemab among them there may be a silver lining to ceding first-mover advantage to Aduhelm.

    After decades of expensive but thus far largely fruitless research trials, the CEO of pharma giant Eli Lilly, David Ricks, said his firm was “getting closer and closer to the goal” after a positive set of Phase Two results for its offering, donanemab.

    Speaking at CNBC’s Healthy Returns Summit in May, a month before the FDA’s approval for rival Biogen’s Aduhelm, he said his team felt “good about the probability of success,” and said he wanted to explore an “accelerated” route too, using what he called “adaptative pathways at the FDA to consider looking at data sooner” that “should be applied in a serious and widespread condition like Alzheimer’s.”

    However, he acknowledged that recruitment for the next phase of trials required a significantly larger cohort of participants, and given that it would last 18 months, he did not expect a new approved product before late 2023 at the earliest.

    Several experts told CNBC the Biogen drug’s unique threshold for regulatory approval, with treatment potential seeming to trump uncertain real-world benefits, could reinvigorate efforts by competitors like Lilly, who are focused on developing drugs that rely on relatively similar techniques.

    The Future Of Alzheimers Disease Treatment

    The future of Alzheimers disease: aducanumab

    If you are looking for a way to stop cognitive decline in its tracks and kick frustrating drugs to the curb, Dr. Ken Sharlins Brain Tune Up! Protocol may be just the solution. This carefully developed, practice-proven treatment has helped patients achieve milestones once thought to be impossible.

    • Results vary from person to person, but many experience some, if not all, of the following benets:
    • Clearer memory as measured by higher scores on the Montreal Cognitive Assessment test after completing the program.
    • Better day-to-day functioning on completing regular daily activities with ease, and fewer symptoms as measured by the MSQ . The average decrease is 40 percent.
    • Improved condence. Imagine, no longer struggling for the right words, being more easily able recall family members names, and experiencing higher energy levels and a better mood. This improves condence and quality of life.

    Recommended Reading: Senile Dementia Of Alzheimer’s Type

    Analysis Of Clinical Trials Targeting Biomarkers

    Several reasons have been proposed for the lack of efficacy of pathology targeted treatment in clinical trials. Firstly, it has been suggested that the dose used to affect the disease could be inadequate or result in unacceptable adverse effects. One of the earliest clinical trials was effective in reducing amyloid concentrations in the brain. Unacceptable levels of encephalomeningitis developed, however, and the trial was terminated. This set the tone for future investigations, and subsequent trials focusing on amyloid immune treatments have used doses to minimise the adverse effects rather than maximise the benefits. Many trial regimens were terminated early as a precaution when there was evidence of inflammatory changes or microhaemorrhages in the brain, although some argued that this could have been early evidence of the immunotherapy efficacy rather than a risk of future encephalitis. Additionally, the human blood-brain barrier is much more discriminating than that of lower species. Therefore, higher concentrations may be required to achieve the therapeutic effect seen in animal models. For instance, solanezumab penetration into the central nervous system is only 0.1% to 0.3% of the concentration measured in plasma. Aducanumab and gantenerumab showed a better and more clinically meaningful outcome when higher doses were used.14

    RELATED ARTICLES

    Most Popular